No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $34
OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
OnKure Therapeutics Analyst Ratings
Express News | Onkure Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $34 From $40
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $31